# Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

> **NCT00083993** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 1236 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** Temsirolimus (CCI-779) for 34 months
- **DRUG:** Letrozole for 34 months

## Key facts

- **NCT ID:** NCT00083993
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 1236 (—)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083993, "Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00083993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*